CABA241220P12500
- 9.30
- 0.000.00%
Cabaletta Bio Newsroom
Top Premarket Gainers
Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Cabaletta Bio to Advance, Super Micro Computer to Decline
12 Health Care Stocks Moving In Friday's Pre-Market Session
Express News | Cabaletta Bio Shares Resume Trade
Express News | Cabaletta Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Up 30.2%
Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio Reports Q3 2024 Financial Results
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $12 to $25
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Express News | Cabaletta Bio, Inc. : Wells Fargo Cuts Target Price to $12 From $20
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Strong Momentum and Promising Data Drive Buy Opportunity for Cabaletta Bio's CABA-201
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Cabaletta Bio Reports Q3 EPS (62c), Consensus (61c)